학술논문
Clinical parameters affecting survival outcomes in patients with low-grade serous ovarian carcinoma: an international multicentre analysis
Document Type
article
Author
May, Taymaa; Bernardini, Marcus; Lheureux, Stephanie; Aben, Katja KH; Bandera, Elisa V; Beckmann, Matthias W; Benitez, Javier; Berchuck, Andrew; Bjørge, Line; Carney, Michael E; Cramer, Daniel W; deFazio, Anna; Dörk, Thilo; Eccles, Diana M; Friedlander, Michael; García, María Jose; Goode, Ellen L; Hein, Alexander; Høgdall, Claus K; Jensen, Allan; Johnatty, Sharon; Kennedy, Catherine J; Kiemeney, Lambertus A; Kjær, Susanne K; Kupryjańczyk, Jolanta; Matsuo, Keitaro; McGuire, Valerie; Modugno, Francesmary; Paddock, Lisa E; Pejovic, Tanja; Phelan, Catherine M; Riggan, Marjorie J; Rodriguez-Antona, Cristina; Rothstein, Joseph H; Sieh, Weiva; Song, Honglin; Terry, Kathryn L; van Altena, Anne M; Vanderstichele, Adriaan; Vergote, Ignace; Thomsen, Liv Cecilie Vestrheim; Webb, Penelope M; Wentzensen, Nicolas; Wilkens, Lynne R; Ziogas, Argyrios; Jiang, Haiyan; Tone, Alicia
Source
Canadian Journal of Surgery. 66(3)
Subject
Language
Abstract
BackgroundWomen with low-grade ovarian serous carcinoma (LGSC) benefit from surgical treatment; however, the role of chemotherapy is controversial. We examined an international database through the Ovarian Cancer Association Consortium to identify factors that affect survival in LGSC.MethodsWe performed a retrospective cohort analysis of patients with LGSC who had had primary surgery and had overall survival data available. We performed univariate and multivariate analyses of progression-free survival and overall survival, and generated Kaplan-Meier survival curves.ResultsOf the 707 patients with LGSC, 680 (96.2%) had available overall survival data. The patients' median age overall was 54 years. Of the 659 patients with International Federation of Obstetrics and Gynecology stage data, 156 (23.7%) had stage I disease, 64 (9.7%) had stage II, 395 (59.9%) had stage III, and 44 (6.7%) had stage IV. Of the 377 patients with surgical data, 200 (53.0%) had no visible residual disease. Of the 361 patients with chemotherapy data, 330 (91.4%) received first-line platinum-based chemotherapy. The median follow-up duration was 5.0 years. The median progression-free survival and overall survival were 43.2 months and 110.4 months, respectively. Multivariate analysis indicated a statistically significant impact of stage and residual disease on progression-free survival and overall survival. Platinum-based chemotherapy was not associated with a survival advantage.ConclusionThis multicentre analysis indicates that complete surgical cytoreduction to no visible residual disease has the most impact on improved survival in LGSC. This finding could immediately inform and change practice.